Technology ID
TAB-2744
Virus Replicon Particles as Rift Valley Fever Vaccines
E-Numbers
E-272-2013-0
Lead Inventor
Dodd, Kimberly (CDC)
Co-Inventors
Albarino, Cesar (CDC)
Bird, Brian (CDC)
Nichol, Stuart (CDC)
Applications
Vaccines
Therapeutics
Research Materials
Occupational Safety and Health
Diagnostics
Consumer Products
Therapeutic Areas
Ophthalmology
Oncology
Infectious Disease
Immunology
Endocrinology
Dental
Cardiology
Development Stages
Pre-Clinical (in vitro)
Development Status
- In vitro data available
- In vivo data available (animal)
Research Products
Antibodies
Lead IC
CDC
ICs
CDC
Rift Valley fever (RVF) virus primarily infects animals but also has the capacity to infect humans. The disease causes abortion and death among RVF-infected livestock, resulting in substantial economic loss to people living in many parts of Africa and Arabian Peninsula. Currently, there is no commercial vaccine for RVF. CDC scientists have developed a RVF virus replicon particle (VRP) vaccine candidate. Research findings revealed that immunization of mice with a single dose of the RVF-VRP was found to be safe and elicited immune response that offered 100% protection following exposure to lethal dose of virulent virus. RVF-VRPs have the potential to become effective and efficient RVF vaccines in livestock animals and humans.
Commercial Applications
- Rift Valley fever vaccine for livestock and/or humans
- VRPs may serve as useful laboratory tool to study the basic mechanisms of virus replication, assembly, kinetics, and virus maturation
Competitive Advantages
- Murine survival study showed single-dose immunization completely protected mice against a virulent RVFV challenge at 100,000-fold greater than the 50% lethal dose (LD(50))
- Rapid onset of a systematic antiviral response suggests conference of early protection
- Low genetic diversity for RVF virus indicates a strong potential for broad-use effectiveness with this vaccine
Licensing Contact: